Lasting Effect Consumer Pharma

Company Overview

Snapshot

Founded in March 2020 by David Tavor, Igal Pikovsky, and Eli Heldman, Lasting Effect Consumer Pharma operates with 1–10 employees. The company has raised $1.85M across two funding rounds from three investors. In January 2023, the company received a grant from the Israel Innovation Authority.

Business overview

Lasting Effect Consumer Pharma develops pharmaceutical therapeutics utilizing a proprietary buccal extended-release drug delivery system. Their technology involves adhesive tablets designed to attach to the oral mucosa, facilitating continuous administration of active ingredients either topically or systemically, bypassing the digestive tract. This system addresses challenges such as dysphagia and administration compliance, serving markets with applications like saliva-stimulating treatments for dry mouth (xerostomia), anti-bacterial formulations for gingivitis, and a non-invasive solution for late-stage Parkinson’s disease to provide prolonged dopamine secretion. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Drug Delivery and Pharmaceuticals.

Company Intelligence Q&A

When was Lasting Effect Consumer Pharma founded?

Lasting Effect Consumer Pharma was founded in March 2020.

Who are the founders of Lasting Effect Consumer Pharma?

The founders of Lasting Effect Consumer Pharma are David Tavor, Igal Pikovsky, and Eli Heldman.

What is Lasting Effect Consumer Pharma's primary sector?

Lasting Effect Consumer Pharma's primary sector is Health Tech & Life Sciences.

What is the total capital raised by Lasting Effect Consumer Pharma?

Lasting Effect Consumer Pharma has raised a total of $1.85M.

What is the core technology developed by Lasting Effect Consumer Pharma?

Lasting Effect Consumer Pharma develops pharmaceutical therapeutics based on a proprietary buccal extended-release drug delivery system, utilizing adhesive tablets for continuous drug administration via the oral mucosa.